Cargando…
Axitinib/pembrolizumab: Tumour-lysis-syndrome: case report
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222139/ http://dx.doi.org/10.1007/s40278-020-78251-5 |
Ejemplares similares
-
Pembrolizumab‐axitinib‐induced tumor lysis syndrome in a patient with metastatic renal cancer
por: Shah, Manan, et al.
Publicado: (2020) -
Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation
por: Vlachostergios, Panagiotis J.
Publicado: (2020) -
Multiple drugs: Tumour lysis syndrome and aplasia: case report
Publicado: (2022) -
Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)
por: Gurruchaga Sotés, Ibon, et al.
Publicado: (2021) -
Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib
por: Nishimoto, Koshiro, et al.
Publicado: (2022)